中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

514 records (took 0.051 seconds)

    Pharmaceutical compositions for high-capacity targeted delivery
    41.
    发明授权
    Pharmaceutical compositions for high-capacity targeted delivery 有权

    公开(公告)号：US10105446B2

    公开(公告)日：2018-10-23

    申请号：US15285916

    申请日：2016-10-05

    Applicant: Wake Forest University Health Sciences

    Inventor： William H. Gmeiner

    IPC: C12N15/115 ,  C12N15/117 ,  A61K47/48 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/337

    Abstract: Provided herein are aptamers and pharmaceutical compositions comprising the same. In some embodiments, the aptamer selectively binds a protein of interest such as an extracellular receptor protein of interest (e.g., a cancer cell extracellular receptor protein, which may be differentially expressed in some embodiments). In some embodiments, the aptamer is directly linked by covalent bonding (e.g., via a geminal diamine linkage) to from 2 to 10 toxin compounds. Also provided herein is a method of selecting an aptamer that specifically binds to a protein expressed by a cell of interest, wherein in some embodiments the aptamer comprises at least one binding site for one or more active compounds. In some embodiments, primer regions flanking the variable region of the aptamers in the pool contains from 1 to 10 mismatches with respect to said forward or reverse primer.

    EPHA3 AND MULTI-VALENT TARGETING OF TUMORS
    42.
    发明申请
    EPHA3 AND MULTI-VALENT TARGETING OF TUMORS 审中-公开

    公开(公告)号：US20180244745A1

    公开(公告)日：2018-08-30

    申请号：US15958608

    申请日：2018-04-20

    Applicant: Wake Forest University Health Sciences

    Inventor： Waldemar Debinski ,  Carla Lema Tome ,  Sara Ferluga ,  Poonam S. Sonawane

    IPC: C07K14/705 ,  C07K14/52 ,  C07K14/54 ,  G01N33/574

    Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Ra2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.

    METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH PROSTATE CANCER RISK
    48.
    发明申请
    METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH PROSTATE CANCER RISK 审中-公开

    公开(公告)号：US20180187265A1

    公开(公告)日：2018-07-05

    申请号：US15675273

    申请日：2017-08-11

    Applicant: Wake Forest University Health Sciences

    Inventor： Jianfeng Xu ,  Siqun Lilly Zheng ,  Jielin Sun ,  Andrew Karim Kader

    IPC: C12Q1/6886

    CPC classification number: C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/172

    Abstract: The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and/or chemoprevention.

Patent Agency Ranking